Karen Pinachyan

Head of Global Medical Affairs for Hematology
CSL Behring

​

Karen Pinachyan, MD, currently holds the position of Head of Global Medical Affairs for the Hematology Therapeutic Area at CSL Behring. In this role, he directs the medical affairs strategy and initiatives for CSL Behring’s portfolio addressing congenital and acquired bleeding disorders, including plasma-derived and recombinant protein-based therapeutic solutions as well as a commercialized gene therapy. Previously, Karen served as the Head of Medical Affairs for the European Region at CSL Behring, overseeing the strategic direction of medical affairs activities across the company's portfolio in immunology, respiratory, hematology, cardiology, and transplantation.
Karen completed his residency in otolaryngology and head & neck surgery at Marseille University Hospital in France, where he also gained experience in toxicology and pharmacovigilance. During his residency, he pursued additional academic endeavors, earning a Master’s degree in management and a diploma in Public Health. His thesis focused on orphan drug development incentives and their significance for healthcare systems, patient communities, and the biotechnology industry. Transitioning to the biotechnology sector, Karen led successful applications for Orphan Drug Designation for the lead compound from both the European Medicines Agency and the US FDA at a startup company in Marseille. Prior to joining CSL Behring in 2019, Karen held positions in medical affairs and clinical development at Boehringer Ingelheim, Octapharma, and Roche across various locations in Europe.

 

Speech title & Synopsis

Harnessing the Power of Gene Therapy: Crafting the Future of Healthcare with Advanced Therapy Medicinal Products (ATMPs)

Advanced Therapy Medicinal Products (ATMPs), including gene therapies, represent a groundbreaking advance in medical science. Gene therapy has evolved from a theoretical idea to a medical reality, offering potential cures for genetic disorders. Advances in molecular biology and genetic engineering have transformed the field, enabling therapies that address the root causes of diseases. By inserting functional genes into patients' cells, gene therapy now provides long-term benefits and significantly improves patients' quality of life.

A notable example of gene therapy's impact is in treating hemophilia. Hemophilia, a genetic disorder that impairs blood clotting, has historically required frequent and costly treatments. Gene therapy has revolutionized this by providing a long-term solution. Recently, several AAV-based gene therapies that deliver functional genes promoting the production of clotting factors have been approved for clinical use. These treatments significantly reduce bleeding episodes and the need for regular clotting factor infusions, allowing patients to lead more normal and active lives.

Developers face challenges such as ensuring long-term efficacy, managing safety concerns, and navigating regulatory landscapes. The future focus is on enhancing precision, safety, and accessibility of gene therapies. Collaboration among researchers, clinicians, and policymakers is vital to overcoming these challenges and advancing the field.

Gene therapy represents a major medical innovation, offering hope to millions. By understanding its development, impacts, and future directions, we can work towards a future where genetic diseases are effectively managed or even eradicated.